Kairos Pharma, LTD.
KAPA- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001962011
No open-market purchases or sales by Kairos Pharma, LTD. insiders were filed in the last 90 days; 14 institutions reported holding it in 13F filings for Q2 2026, worth $371.1K in total; no superinvestor holds it.
Q3 2025 vs. Q2 2025
How the institutions holding Kairos Pharma, LTD. changed between Q2 2025 and Q3 2025.
All holders in Q3 2025All holders in Q2 2025
| Measure | Q2 2025 | Q3 2025 | Change |
|---|---|---|---|
| Holders | 10 | 14 | +4 |
| Shares | 218.7K | 445.0K | +226.3K (+103.5%) |
| Value | $172.9K | $505.8K | +$333.0K (+192.6%) |
New holders (6)
Institutions that held Kairos Pharma, LTD. at the end of Q3 2025 but not at the end of Q2 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Vanguard Group Inc | 131,828 | $154.2K | 0.00% |
| Two Sigma Investments, LP | 45,789 | $53.6K | 0.00% |
| State Street Corp | 24,100 | $28.2K | 0.00% |
| FNY Investment Advisers, LLC | 23,500 | $27.0K | 0.01% |
| Quadrature Capital Ltd | 14,887 | $17.4K | 0.00% |
| Royal Bank of Canada | 1,000 | $1.00K | 0.00% |
Sold out (2)
Institutions that held Kairos Pharma, LTD. at the end of Q2 2025 and filed for Q3 2025 without it.
| Institution | Shares, Q2 2025 | Value, Q2 2025 |
|---|---|---|
| HRT Financial LP | 13,239 | $9.00K |
| Citigroup Inc | 5,499 | $3.90K |